Scarica l'app Stockscreener
58.39
0.78%
0.45
Dopo l'orario di chiusura:
58.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content - finance.biggo.com
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
(EXEL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exelixis, Inc. (EXEL) stock price, news, quote and history - uk.finance.yahoo.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Shares Rising on CABOMETYX Revenue - FXEmpire
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com South Africa
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance Australia
Return on equity % of Exelixis, Inc. – HAN:EX9 - TradingView
How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension - webull.com
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - finance.yahoo.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - Yahoo Finance
Exelixis (EXEL) Gains Ground: Shares Rise 1.63% to $58.15 as Buyers Hold Mid-Range SupportSize Factor - siam.in
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Exelixis (EXEL) Slips 0.22% to $58.36, Key Support and Resistance in FocusRisk Reward Setups - careplusvn.com
Exelixis (EXEL) Institutional Ownership 2026 $EXEL - MarketBeat
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B - Yahoo Finance
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? - finance.yahoo.com
Exelixis Inc (EX9.MU) Stock Price, News, Quote & History - Yahoo Finance
Exelixis Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle - Yahoo Finance
Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade) - Seeking Alpha
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Potential Amidst a Competitive Biotech Landscape - DirectorsTalk Interviews
Analysts Offer Insights on NA Companies: Exelixis (EXEL) and HEICO (HEI) - The Globe and Mail
Exelixis FDA Delay Moves Zanzalintinib Decision to March 2027 - TechStock²
Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value - webull.com
Form 8K Exelixis Inc For: 11 September By Investing.com - Investing.com Australia
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term - Stocktwits
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug - Investor's Business Daily
FDA extends review of Exelixis drug application for metastatic colorectal cancer - Investing.com Nigeria
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In - Benzinga
EXEL Looks 21.5% Overvalued on GF Value™ as PDUFA Delay Sparks Volatility - GuruFocus
FDA extends review of Exelixis’ colorectal cancer drug candidate - endpoints.news
US FDA extends review of Exelixis’ cancer drug - WSAU
FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027 - AllSci
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months - Yahoo Finance
US FDA extends review of Exelixis' cancer drug - Reuters
Why is Exelixis stock sliding today? By Investing.com - Investing.com Canada
Exelixis stock falls as FDA extends zanzalintinib review By Investing.com - Investing.com South Africa
Exelixis stock falls as FDA extends zanzalintinib review - investing.com
EXEL Looks 24.3% Overvalued on GF Value™ - GuruFocus
Form 8K Exelixis Inc For: 11 September - Investing.com India
FDA Extends Review Timeline for Exelixis Cancer Drug - TipRanks
U.S. FDA extends review of Exelixis' cancer drug - Yahoo Finance
Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules - Yahoo Finance
La FDA américaine prolonge l'examen du médicament anticancéreux d'Exelixis - TradingView
Die US-amerikanische FDA verlängert die Prüfung des Krebsmedikaments von Exelixis - TradingView
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):